ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock par value $0.012 per share
Symbol
ORMP on Nasdaq
Shares outstanding
39,608,807
Price per share
$3.39
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
11,032,419
Total reported value
$31,445,392
% of total 13F portfolios
0%
Share change
-77,514
Value change
-$220,532
Number of holders
54
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BML Investment Partners, L.P. 8.3% +25% $11,276,231 +$2,207,630 3,287,531 +24% Leonard Braden Michael 31 Dec 2025
KIDRON NADAV 7.6% $6,638,633 3,116,729 Nadav Kidron 11 Feb 2025

As of 31 Dec 2025, 54 institutional investors reported holding 11,032,419 shares of ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP). This represents 28% of the company’s total 39,608,807 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) together control 27% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BML Capital Management, LLC 8% 3,167,231 0% 8% $9,026,608
Aquamarine Financial (Cayman) Ltd 5% 1,973,057 0% 0.46% $5,623,212
SB Capital Management Inc 4.8% 1,900,000 0% 2% $5,415,000
Murchinson Ltd. 3.4% 1,340,247 -23% 2.4% $3,819,704
BOOTHBAY FUND MANAGEMENT, LLC 1.5% 612,160 -28% 0.05% $1,744,656
MARSHALL WACE, LLP 0.65% 259,055 0% $738,308
Rathbones Group PLC 0.59% 233,018 0% 0% $664,101
CITADEL ADVISORS LLC 0.49% 196,020 +75% 0% $558,657
DIMENSIONAL FUND ADVISORS LP 0.38% 150,471 +2% 0% $428,843
RENAISSANCE TECHNOLOGIES LLC 0.37% 147,500 -0.94% 0% $420,375
BANK OF AMERICA CORP /DE/ 0.36% 142,243 -5% 0% $405,393
WELLS FARGO & COMPANY/MN 0.33% 130,586 +0.38% 0% $372,169
BlackRock, Inc. 0.23% 90,212 -18% 0% $257,104
JANE STREET GROUP, LLC 0.2% 78,259 +31% 0% $223,038
Squarepoint Ops LLC 0.15% 58,272 +95% 0% $166,075
HRT FINANCIAL LP 0.12% 46,091 0% $131,000
Connor, Clark & Lunn Investment Management Ltd. 0.11% 43,735 +55% 0% $124,645
RBF Capital, LLC 0.11% 42,947 0% 0.01% $122,399
Quadrature Capital Ltd 0.11% 41,734 0% $118,942
XTX Topco Ltd 0.1% 38,182 +60% 0% $108,819
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.07% 25,984 -29% 0% $74,054
Point72 Asset Management, L.P. 0.06% 25,442 0% $72,510
GEODE CAPITAL MANAGEMENT, LLC 0.06% 24,282 0% 0% $69,203
TWO SIGMA SECURITIES, LLC 0.06% 23,143 0.01% $65,958
PRELUDE CAPITAL MANAGEMENT, LLC 0.05% 21,613 0% $61,597

Institutional Holders of ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 11,032,419 $31,445,392 -$220,532 $2.85 54
2025 Q3 9,209,933 $24,309,179 +$25,894 $2.64 47
2025 Q2 7,251,222 $16,313,647 -$1,132,788 $2.25 47
2025 Q1 7,771,787 $16,633,500 +$194,000 $2.14 52
2024 Q4 7,666,141 $18,551,607 +$1,150,587 $2.42 56
2024 Q3 6,959,875 $16,982,253 +$2,490,137 $2.44 55
2024 Q2 5,933,749 $15,249,519 +$1,726,907 $2.57 58
2024 Q1 5,261,652 $15,365,000 +$367,171 $2.92 51
2023 Q4 5,157,802 $11,912,739 +$6,481,828 $2.31 56
2023 Q3 2,294,903 $5,988,449 -$130,636 $2.61 55
2023 Q2 2,276,672 $8,150,136 -$6,048,074 $3.58 50
2023 Q1 4,261,808 $9,288,923 -$8,600,260 $2.18 58
2022 Q4 3,602,106 $43,330,122 +$3,052,928 $12.03 75
2022 Q3 3,938,125 $25,517,588 -$15,544,475 $6.48 66
2022 Q2 6,646,450 $30,636,409 -$17,757,938 $4.58 81
2022 Q1 9,033,365 $78,273,671 -$349,248 $8.65 99
2021 Q4 8,576,111 $122,411,193 +$40,878,901 $14.28 114
2021 Q3 5,412,384 $118,854,258 +$35,544,918 $21.98 91
2021 Q2 3,842,761 $51,413,524 +$35,140,443 $13.38 73
2021 Q1 1,235,726 $64,175,840 +$52,410,474 $10.16 43
2020 Q4 1,455,367 $6,169,000 -$1,608,413 $4.24 36
2020 Q3 2,003,232 $5,190,000 +$1,670,327 $2.61 34
2020 Q2 1,349,404 $4,725,000 +$2,515,869 $3.53 31
2020 Q1 624,185 $1,899,000 -$91,414 $3.04 29
2019 Q4 624,437 $3,215,000 -$401,395 $5.14 30
2019 Q3 759,036 $2,420,000 -$260,031 $3.19 28
2019 Q2 839,001 $3,010,000 -$842,076 $3.59 26
2019 Q1 1,073,145 $3,905,000 -$2,620,760 $3.64 25
2018 Q4 1,898,942 $5,699,000 +$412,711 $3.00 24
2018 Q3 1,741,007 $8,449,000 +$7,167,466 $4.85 28
2018 Q2 263,431 $1,958,000 +$6,399 $7.43 21
2018 Q1 256,435 $1,666,000 -$820,544 $6.51 20
2017 Q4 377,714 $3,402,549 +$790,106 $9.00 27
2017 Q3 274,779 $2,725,000 +$1,262,094 $9.92 22
2017 Q2 148,752 $1,157,000 +$276,760 $7.78 21
2017 Q1 148,282 $909,000 +$37,679 $6.10 20
2016 Q4 139,267 $850,000 -$374,754 $6.05 23
2016 Q3 181,737 $1,320,000 -$246,428 $7.26 21
2016 Q2 220,940 $1,841,000 +$300,003 $8.34 23
2016 Q1 201,186 $1,318,000 -$124,121 $6.65 24
2015 Q4 210,282 $1,781,840 +$388,209 $8.55 23
2015 Q3 156,424 $854,000 -$1,037,671 $5.47 18
2015 Q2 334,950 $1,904,000 -$1,476,942 $5.68 13
2015 Q1 543,520 $3,371,822 -$1,225,552 $6.37 14
2014 Q4 824,403 $3,758,000 -$864,806 $4.56 19
2014 Q3 1,375,959 $11,127,000 -$423,614 $8.07 18
2014 Q2 1,426,930 $13,726,430 +$928,265 $9.62 22
2014 Q1 1,311,737 $15,304,000 +$5,082,819 $11.78 21